Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

Vanderbilt University Medical Center

Status and phase

Completed

Phase 1

Conditions

Rectal Cancer

Treatments

Device: PET imaging with [18F]-FLT

Drug: [18F]-fluorodeoxythymidine

Study type

Interventional

Funder types

Other

Identifiers

NCT01207895

VICC GI 0993

Details and patient eligibility

About

The purpose of this study is to determine if positron emission tomography (PET) imaging with an imaging agent called 18F-fluorodeoxythymidine([18F]-FLT) will allow investigators to measure how well tumor(s) respond to treatment without taking a tissue sample (biopsy). Additionally, the investigators want to determine if it is possible to predict how well tumor(s) might respond to treatment with [18F]-FLT PET imaging.

Enrollment

5 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects with known rectal cancer.
Subjects must have signed an approved consent form.
Subjects must be 18 years of age or older.

Exclusion criteria

Children less than 18 are excluded.
Pregnant women and women who are breast feeding will be excluded from this study. A serum beta HCG will also be performed for each pre-menopausal female subject.
Patients who are acutely ill who are deemed by their treating physician as not suitable candidates for this study